+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07633626

Study of Vortioxetines Impact on Brain Function in Adults With ALK-positive Non-Small Cell Lung Cancer Receiving Lorlatinib

Led by Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Updated on 2026-06-08

24

Participants Needed

1

Research Sites

35 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether vortioxetine, an antidepressant with cognitive-enhancing effects, can reduce neurological and cognitive side effects caused by lorlatinib in patients with non-small cell lung cancer NSCLC that have ALK or ROS1 gene rearrangements. Lorlatinib is a targeted cancer therapy effective against these cancers but causes neuropsychological adverse events like cognitive impairment, mood changes, and speech problems in many patients. This observational study focuses on adults receiving lorlatinib who develop these side effects. Twenty-four adult patients with ALKROS1-positive NSCLC who are prescribed vortioxetine 10-20 mg per day as part of their standard care will be followed. The study documents changes in cognitive function, mood, and quality of life over multiple time points at the start, week 6, week 12, and month 6. Patients will continue their usual lorlatinib treatment while being monitored for how vortioxetine affects their neurological symptoms. Participants will undergo comprehensive neuropsychological testing and quality-of-life questionnaires at these intervals to measure various cognitive domains such as psychomotor speed, attention, memory, language, and executive function. Depressive symptoms, functional capacity, work limitations, and tumor response to lorlatinib will also be assessed. Adverse events will be monitored throughout the study and for 30 days after the last visit. The study lasts at least six months, allowing detailed observation of cognitive and mood changes during vortioxetine use.

CONDITIONS

Brief Title

Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib

Research Team

F

Felipe Canro, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here